MXCT - MaxCyte GAAP EPS of -$0.06 beats by $0.03 revenue of $10.6M beats by $0.17M
- MaxCyte press release ( NASDAQ: MXCT ): Q3 GAAP EPS of -$0.06 beats by $0.03 .
- Revenue of $10.6M (+5.0% Y/Y) beats by $0.17M .
- 2022 Revenue Guidance
- We expect core business revenue in 2022 to grow approximately 30% compared to 2021. We continue to expect SPL Program-related revenue to be approximately $4.0 million in 2022.
For further details see:
MaxCyte GAAP EPS of -$0.06 beats by $0.03, revenue of $10.6M beats by $0.17M